{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:24:09Z","timestamp":1787315049790,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.eprac.2026.07.018","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:20:34Z","timestamp":1785885634000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Efficacy of Glucagon Like Peptide-1 Receptor Agonism-Based Therapies in End-Stage Renal Disease: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4915-8805","authenticated-orcid":false,"given":"Deep","family":"Dutta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sweekruti","family":"Jena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abul Bashar Mohammad","family":"Kamrul-Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saptarshi","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritin","family":"Mohindra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2026.07.018_bib1","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001163","article-title":"Population-based trends in obesity and kidney transplantation among patients with end-stage kidney disease","volume":"7","author":"Wakam","year":"2021","journal-title":"Transpl Direct"},{"key":"10.1016\/j.eprac.2026.07.018_bib2","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1111\/dom.70391","article-title":"Impact of glucagon-like peptide-1 receptor agonism-based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: an updated systematic review and meta-analysis","volume":"28","author":"Dutta","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2026.07.018_bib3","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.eprac.2025.06.005","article-title":"Comparative effectiveness of Glucagon-like Peptide-1- receptor agonists in patients with heart failure with preserved or minimally reduced ejection fraction: a comprehensive Bayesian network meta-analysis and network meta-regression","volume":"31","author":"Khalil","year":"2025","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2026.07.018_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102539","article-title":"Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: a meta-analysis","volume":"16","author":"Dutta","year":"2022","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"10.1016\/j.eprac.2026.07.018_bib5","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.numecd.2023.03.023","article-title":"Glucagon-like peptide 1 receptor agonists in end-staged kidney disease and kidney transplantation: a narrative review","volume":"33","author":"Clemens","year":"2023","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.eprac.2026.07.018_bib6","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s40262-018-0649-2","article-title":"Pharmacokinetics, safety and tolerability of oral semaglutide in subjects with renal impairment","volume":"57","author":"Granhall","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eprac.2026.07.018_bib7","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s40262-017-0528-2","article-title":"Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon-like Peptide-1 analog, in subjects with and without renal impairment","volume":"56","author":"Marbury","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eprac.2026.07.018_bib8","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1365-2125.2009.03536.x","article-title":"Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide","volume":"68","author":"Jacobsen","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.eprac.2026.07.018_bib9","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40262-021-01012-2","article-title":"Effects of renal impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist tirzepatide","volume":"60","author":"Urva","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eprac.2026.07.018_bib10","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.eprac.2026.07.018_bib12","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.eprac.2026.07.018_bib13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.eprac.2026.07.018_bib14","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.eprac.2026.07.018_bib15","doi-asserted-by":"crossref","DOI":"10.1177\/20543581251324588","article-title":"The real-world use of semaglutide to promote weight loss in obese adults with hemodialysis: a multicenter cross-sectional descriptive study","volume":"12","author":"Couture","year":"2025","journal-title":"Can J Kidney Health Dis"},{"key":"10.1016\/j.eprac.2026.07.018_bib16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s41100-025-00628-5","article-title":"Semaglutide in people with obesity and type 2 diabetes on hemodialysis: a prospective analysis of glycemic and weight outcomes","volume":"11","author":"Hayashi","year":"2025","journal-title":"Ren Replace Ther"},{"key":"10.1016\/j.eprac.2026.07.018_bib17","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1111\/dom.15967","article-title":"Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: a prospective, observational, open-label study","volume":"26","author":"Vanek","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2026.07.018_bib18","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.eprac.2024.07.008","article-title":"The use of semaglutide in patients with renal Failure-A retrospective cohort study","volume":"30","author":"Long","year":"2024","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2026.07.018_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.70344","article-title":"Bridging the gap to waitlist activation: semaglutide\u2019s weight loss efficacy and safety in patients with obesity on dialysis seeking kidney transplantation","volume":"39","author":"Wade","year":"2025","journal-title":"Clin Transpl"},{"key":"10.1016\/j.eprac.2026.07.018_bib20","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000527919","article-title":"Efficacy and safety of semaglutide, a glucagon-like Peptide-1 receptor agonist in real-life: a case series of patients in maintenance incremental hemodialysis","volume":"12","author":"De La Flor","year":"2022","journal-title":"Case Rep Nephrol Dial"},{"key":"10.1016\/j.eprac.2026.07.018_bib21","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3390\/medicina62020386","article-title":"Preliminary real-world experience with semaglutide in Obese patients with type 2 diabetes on chronic hemodialysis: a multicenter pilot study","volume":"62","author":"Yugueros","year":"2026","journal-title":"Medicina (Mex)"},{"key":"10.1016\/j.eprac.2026.07.018_bib22","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.japh.2023.06.003","article-title":"Glucagon-like peptide-1 receptor agonists use for type 2 diabetes mellitus in end-stage renal disease","volume":"63","author":"Thomas","year":"2023","journal-title":"J Am Pharm Assoc"},{"key":"10.1016\/j.eprac.2026.07.018_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2026.1805015","article-title":"Real-world use of semaglutide in patients with type 2 diabetes and end-stage renal disease: a multicenter retrospective cohort study","volume":"17","author":"Alkhezi","year":"2026","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.eprac.2026.07.018_bib24","doi-asserted-by":"crossref","DOI":"10.2337\/dc26-0112","article-title":"Safety of semaglutide after dialysis initiation: an individual-level pooled analysis","author":"Klein","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.07.018_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/frtra.2025.1623096","article-title":"Elective semaglutide prescription enabled waitlisting and transplantation of otherwise ineligible obese renal transplant candidates","volume":"4","author":"Navaux","year":"2025","journal-title":"Front Transpl"},{"key":"10.1016\/j.eprac.2026.07.018_bib26","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.71511","article-title":"Outcomes of semaglutide use in achieving target body mass index before renal transplant in five end-stage renal disease patients: a case series","author":"Al-saad","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.eprac.2026.07.018_bib27","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1111\/dom.16484","article-title":"Efficacy and tolerance of liraglutide for weight loss in obese, type 2 diabetes and haemodialysis patients","volume":"27","author":"Touzot","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2026.07.018_bib28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000510613","article-title":"The glycemic effect of liraglutide evaluated by continuous glucose monitoring in persons with type 2 diabetes receiving dialysis","volume":"145","author":"Bomholt","year":"2021","journal-title":"Nephron"},{"key":"10.1016\/j.eprac.2026.07.018_bib29","first-page":"52","article-title":"Favorable effect on blood volume control in hemodialysis patients with type 2 diabetes after switching from insulin therapy to liraglutide, a human glucagon-like Peptide-1 Analog--Results from a pilot study in Japan-","volume":"42","author":"Kondo","year":"2017","journal-title":"Tokai J Exp Clin Med"},{"key":"10.1016\/j.eprac.2026.07.018_bib30","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2337\/dc15-1025","article-title":"Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: an investigator-initiated, placebo-controlled, double-blind, parallel-group, randomized trial","volume":"39","author":"Idorn","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.07.018_bib31","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/1744-9987.12319","article-title":"Liraglutide improves glycemic and blood pressure control and ameliorates progression of left ventricular hypertrophy in patients with type 2 diabetes mellitus on peritoneal dialysis","volume":"19","author":"Hiramatsu","year":"2015","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.eprac.2026.07.018_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.489","article-title":"Tirzepatide reduces fat mass and provides good glycaemic control in type 2 diabetes patients undergoing haemodialysis: a single-centre retrospective study","volume":"7","author":"Mima","year":"2024","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.eprac.2026.07.018_bib33","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jdiacomp.2017.12.005","article-title":"Improved glycemic control with once-weekly dulaglutide in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring","volume":"32","author":"Yajima","year":"2018","journal-title":"J Diabetes Complications"},{"issue":"1","key":"10.1016\/j.eprac.2026.07.018_bib34","first-page":"34","article-title":"Grupo de Tabajo para el Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal cr\u00f3nica. [Consensus document on treatment of type 2 diabetes in patients with chronic kidney disease]","volume":"34","author":"G\u00f3mez-Huelgas","year":"2014","journal-title":"Nefrol Publicacion Soc Espanola Nefrol"},{"key":"10.1016\/j.eprac.2026.07.018_bib35","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(25)01853-7","article-title":"Global, regional, and national burden of chronic kidney disease in adults, 1990\u20132023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease study 2023","volume":"406","author":"Mark","year":"2025","journal-title":"The Lancet"},{"key":"10.1016\/j.eprac.2026.07.018_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.70136","article-title":"Safety and efficacy of semaglutide in patients with chronic kidney disease, with or without type 2 diabetes: a systematic review and meta-analysis","volume":"8","author":"Abdullah","year":"2025","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.eprac.2026.07.018_bib37","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jdiacomp.2018.05.018","article-title":"The effect of dulaglutide on body composition in type 2 diabetes mellitus patients on hemodialysis","volume":"32","author":"Yajima","year":"2018","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.eprac.2026.07.018_bib38","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1053\/j.ajkd.2005.05.020","article-title":"Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population","volume":"46","author":"Kalantar-Zadeh","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.eprac.2026.07.018_bib39","series-title":"World Obesity Federation Global Obesity Observatory [Internet]","year":"2024"},{"key":"10.1016\/j.eprac.2026.07.018_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165712","article-title":"Effect of the obesity epidemic on kidney transplantation: obesity is independent of diabetes as a risk factor for adverse renal transplant outcomes","volume":"11","author":"Kwan","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.eprac.2026.07.018_bib41","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.pcad.2013.10.005","article-title":"Obesity paradox in end-stage kidney disease patients","volume":"56","author":"Park","year":"2014","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.eprac.2026.07.018_bib42","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.mayocp.2024.01.017","article-title":"Weight loss surgery increases kidney transplant rates in patients with renal failure and obesity","volume":"99","author":"Kukla","year":"2024","journal-title":"Mayo Clin Proc"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26010864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26010864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:39:39Z","timestamp":1787312379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26010864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":41,"alternative-id":["S1530891X26010864"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.07.018","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Glucagon Like Peptide-1 Receptor Agonism-Based Therapies in End-Stage Renal Disease: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}